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Abstract. Background: The clinical significance of the
circulating levels of activin A and matrix metalloproteinase-2
(MMP-2) and -9 (MMP-9) was investigated in patients with
breast cancer (BC) or prostate cancer (PC) with (M1) or
without (M0) bone metastasis. Patients and Methods: MMP-2,
MMP-9 and activin A blood concentrations were measured by
enzyme immunoassays in 79 cancer patients and in 57 healthy
blood donors (HS) who served as a control group. The
diagnostic accuracy of these molecules to discriminate between
M0 and M1 patients was evaluated by the receiver operating
characteristic curve (ROC) and compared to that of tumor
markers CA15.3 or prostate-specific antigen (PSA). Results:
Activin A and MMP-2 were significantly increased in BC and
PC patients as compared to sex-matched HS while MMP-9
levels were more elevated only in the PC patients. Interestingly,
in the PC patients, activin A levels were significantly higher than
those measured in the BC patients. In this latter group, activin A
and CA15.3 but not MMP-2 or MMP-9 were increased in the
M1 patients as compared to M0 patients. Furthermore, a
significant relationship was also highlighted between activin A
concentration and the number of bone metastases and tumor
grade, between MMP-9 and tumor grade, and between MMP-2
and CA15.3. ROC curve analysis showed a good diagnostic
accuracy for activin A and CA15.3 but a poor accuracy for
MMP-2 and MMP-9 in discriminating between M0 and M1
patients. However, CA15.3 retained the best diagnostic accuracy
in this respect. In the PC group, only activin A and PSA levels
were significantly increased in the M1 patients as compared to
the M0 patients. A similar although not statistically significant
trend was noted for MMP-9. Interestingly, a significant correlation
was observed between PSA and activin A and MMP-9, and
between Activin A and Gleason score and the number of
skeletal metastases. ROC curve analysis showed a good
diagnostic accuracy for activin A, MMP-9 and PSA and a poor
diagnostic accuracy for MMP-2 in detecting M1 patients.
However, PSA showed the highest diagnostic accuracy.
Conclusion: Activin A, MMP-2 and MMP-9 may be regarded as
possible therapeutic targets in the treatment of metastatic bone
disease. However, their usefulness as additional markers of bone
metastasis remains to be better defined.
Matrix metalloproteinase-2 (MMP-2) and matrix
metalloproteinase-9 (MMP-9) are zinc-dependent endo-
peptidases mainly devoted to the degradation of
extracellular matrix proteins (1). Growing experimental
evidence suggests that these proteinases may also be
implicated in bone remodeling processes associated with
various physiological and pathological conditions,
including bone metastasis formation (1-3). The
mechanisms by which MMP-2 and MMP-9 may facilitate
bone metastasization have not yet been fully elucidated.
However, recent findings suggest that tumor cells may
secrete and/or induce osteoclasts to release into the bone
microenvironment several proteolytic enzymes, including
MMP-2 and -9, which may degrade bone matrix proteins
thus cleaving a number of growth factors pre-incorporated
in the bone tissue (3, 4). These factors, in turn, may
stimulate tumor cells to release other soluble growth
factors, cytokines, hormones and proteolytic enzymes
which may further promote cell proliferation, migration
and invasion of host tissue, setting up a vicious circle (5).
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Among the growth factors released during these events,
several components of the transforming growth factor ‚
(TGF-‚) superfamily seem to play an active role in the
regulation of the expression levels of MMP-2 and MMP-9
during bone turnover processes associated with skeletal
metastasis (6-9). In this context, recent studies have been
focused on a specific member of this family of growth
factors, namely activin A. In fact, it has been reported that
this multifunctional cytokine appears to be implicated in
the regulation of osteoblastic activity and osteoclast
differentiation and in the modulation of intracellular
MMP-2 and MMP-9 expression levels in osteoblasts, in
osteoclasts and in bone metastatic cells (7-18). On the
basis of these findings, the present study was undertaken
to assess the clinical value of the circulating levels of these
molecules as possible markers of bone metastatic spread
in patients with breast (BC) or prostate cancer (PC).
Patients and Methods
The present study included 57 registered healthy blood donors
(HS) (30 female and 27 male) who served as a control group, 35
patients with histologically proven BC (median age 60, range 36-
77 years) and 44 patients with PC (median age 70, range 56-88
years). Both the BC and the PC groups comprised patients with
localized disease (M0), and patients with bone metastases (M1)
but no clinical evidence of extraskeletal involvement. Bone
metastases were diagnosed by skeletal scintigraphy, skeleton x-
ray or magnetic resonance imaging, or by a combination of these
tests as required. The study was approved by the local ethical
committee and carried out in accordance with the Declaration of
Helsinki (19).
Plasma MMP-2 and MMP-9 and serum activin A assays. As the
measurement of the circulating levels of MMP-2 and MMP-9 in the
serum has been reported to be artificially higher compared to the
values determined in the plasma (20, 21), blood samples obtained
from patients before any surgical and/or clinical treatment were
aliquoted either into EDTA-coated tubes for MMP-2 and -9 assay
or into polycarbonate tubes for activin A assay. The blood in the
polycarbonate tubes was allowed to clot at room temperature.
Samples were then centrifuged at 3500 rpm for 15 min (Hereus
Omnifuge 2.0 RS, Hereus Sepatech, Osterode, Germany). Serum or
plasma aliquots were stored at –80ÆC until assayed. MMP-2, MMP-
9 and activin A levels were determined by commercially available
two-step sandwich enzyme-linked immunosorbent assay (ELISA)
kits according to the manufacturer’s instructions (Biotrak MMP-2
and MMP-9 ELISA kits, Amersham Bioscience, Little Chalfont, UK;
Activin A Assay kit, Oxford Bio-Innovation Ltd, UK). The reported
detection limits were 0.37 ng/ml for MMP-2, 0.6 ng/ml for MMP-9
and <78 pg/ml for activin A.
Serum CA15.3 and PSA. The tumor marker CA15.3 and prostate-
specific antigen (PSA) serum levels were determined in the BC and
PC patients respectively by an automated commercially available
immunoluminometric assay (DiaSorin, Saluggia, Italy). The
reference value and the detection limit reported by the manufacturer
were 30 U/mL and <0.3 U/ml for CA15.3 and 3.2 ng/ml and <0.009
ng/ml for PSA respectively. 
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Table I. Activin A, MMP-2 and MMP-9 blood concentrations in healthy subjects and cancer patients. 
Healthy subjects (HS) Breast cancer patients (BC) Mean CP/HS ratio p-value*
Activin A (pg/ml) 359.8±177.0 932.3±927.1 2.59 <0.0001
(n=30) (n=35)
MMP-2 (ng/ml) 781.4±190.7 1564.3±433.0 2.00 <0.0001
(n=12) (n=29)
MMP-9 (ng/ml) 64.5±39.2ñ 94.5±64.3 1.46 0.2 (n.s.)
(n=12) (n=32)
Healthy subjects (HS) Prostate cancer patients (PC) Mean CP/HS ratio p-value*
Activin A (pg/ml) 437.3±198.4 1055.6±731.7Æ 2.41 <0.0001
(n=27) (n=44)
MMP-2 (ng/ml) 774.2±217.4 1603.5±437.1 2.07 <0.0001
(n=28) (n=32)
MMP-9 (ng/ml) 41.3±41.0 102.4±89.6 2.48 0.016
(n=26) (n=27)
Results are expressed as mean±standard deviation. n=number of evaluable subjects; *Data analysis was computed by the non-parametric Mann-
Whitney U-test; n.s. not significant; ñp=0.039 vs. male HS and Æp=0.027 vs. breast cancer.
Statistical analysis. The statistical analysis was carried out by the
Medcalc 7.4 statistical software package (MEDCALC version 7.4,
Mariakerke, Belgium). Because of the uneven distribution of the
data, as assessed by the D’Agostino-Pearson test for normal
distribution, data analysis was performed where required by the
non-parametric Mann-Whitney U-test and the Kruskall-Wallis
test. The diagnostic sensitivity and the specificity of activin A,
MMP-2, MMP-9, CA15.3 and PSA to discriminate between M0
and M1 patients were determined by the receiver operating
characteristic curve (ROC) analysis (22). The significance of the
difference between the areas under the ROC curves (AUC) was
assessed according to Hanley and McNeil (23). P-values ≤0.05
were considered statistically significant.
Results
Activin A and MMP-2 blood levels were markedly increased
in the BC and PC patients as compared to sex-matched HS
(p<0.0001) while statistically significant higher levels of
MMP-9 were observed only in the PC patients (p=0.016)
(Table I). Interestingly, a slight, statistically significant
increase in activin A concentration was observed in PC
patients as compared to BC patients (p=0.027). In this latter
group, activin A and CA15.3 were more elevated in M1
patients than in M0 patients (2.2- and 4.6-fold, respectively;
p=0.047 and p<0.0001) while no significant difference was
observed for MMP-2 and MMP-9 (p=0.14 and p=0.52,
respectively) (Table II). Interestingly, in these patients a
significant relationship was highlighted between activin A and
the number of bone metastases (p=0.007) and tumor grade
(p=0.046), between MMP-9 and tumor grade (p=0.013), and
between MMP-2 and CA15.3 (p=0.0088) (Table III). ROC
curve analysis showed a fair and good diagnostic performance
for activin A (p=0.031) and CA15.3 (p=0.001), respectively,
and a poor accuracy for MMP-2 (p=0.13) and MMP-9
(p=0.51) in discriminating between the M0 and M1 patients
(Table IV). However, CA15.3 showed the largest AUC which
was significantly higher than that of activin A (p=0.036),
MMP-2 (p=0.01) or MMP-9 (p=0.002) (Figure 1).
Conversely, the combination of CA15.3 with activin A, or
MMP-2, or MMP-9 did not result in a diagnostic accuracy
better than that of CA15.3 alone (data not shown). In the PC
group, activin A and PSA but not MMP-2 blood levels were
significantly increased in the M1 patients as compared to the
M0 patients (p=0.0038; p<0.0001, and p=0.48 respectively)
(Table II). A trend toward higher MMP-9 plasma
concentrations was also noted in the M1 patients (p=0.084)
(Table II). Moreover, in these patients, activin A serum levels
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Table II. Activin A, MMP-2, MMP-9, CA15.3 and PSA circulating levels in patients with (M1) or without (M0) bone metastases.
Parameter No metastasis (M0) Bone metastasis (M1) M1/M0 mean ratio p-value*
Breast cancer
Activin A (pg/ml) 604.9±217.6 1322.6±1261.7 2.19 p=0.047
(n=19) (n=16)
MMP-2 (ng/ml) 1699.6±347.9 1532.5±482.4 0.90 p=0.14 (n.s.)
(n=17) (n=12)
MMP-9 (ng/ml) 104.5±74.4 83.1±50.6 0.79 p=0.52 (n.s.)
(n=17) (n=15)
CA15.3 (U/ml) 17.9±8.1 82.6±123.9 4.6 p<0.0001
(n=18) (n=16)
Prostate cancer
Activin A (pg/ml) 705.9±311.1 1315.3±831.0 1.86 p=0.0038
(n=17) (n=27)
MMP-2 (ng/ml) 1525.5±382.5 1681.4±481.5 1.1 p=0.48 (n.s)
(n=16) (n=16)
MMP-9 (ng/ml) 87.03±103.0 113.05±80.9 1.3 p=0.084 (n.s)
(n=11) (n=16)
PSA (ng/ml) 5.5±5.6 463.7±1207.5 84.3 p<0.0001
(n=15) (n=28)
Results are expressed as mean±SD; n=number of evaluable subjects. Due to missing samples the number of patients in each group may vary.
*Mann-Whitney U-test; n.s.=not significant.
positively correlated with PSA (p=0.005), Gleason score
(p=0.029) and number of bone lesions (p=0.022), while
MMP-9 plasma concentrations were significantly associated
with PSA only (p=0.021) (Table III). In contrast, no
correlation was observed between MMP-2 and the
clinicobiological parameters considered (Table III). ROC
curve analysis showed a good diagnostic accuracy for activin
A, MMP-9 and PSA but a poor diagnostic performance for
MMP-2 in discriminating between the M1 and M0 patients
(Table IV). PSA showed the largest AUC which was
significantly higher than the AUCs of activin A (p=0.0012),
MMP-2 (p=0.006) and MMP-9 (p=0.004) (Figure 1). Again,
the combination of PSA with any of the other markers did
not result in an improved diagnostic performance in detecting
patients with bone metastasis (data not reported).
Discussion
The results showed that the patients with breast or prostate
cancer have increased circulating levels of activin A, MMP-2
and MMP-9 as compared to the sex-matched control group.
These data confirm, in part, previous observations from other
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Table III. Activin A, MMP-2 and MMP-9 distribution in patients with breast cancer or prostate cancer according to some clinicobiological parameters
of progression.
Breast Cancer
Parameter MMP-2 (ng/ml) MMP-9 (ng/ml) Activin A (pg/ml)
Tumor grade
G1 1810.0±187.0 (n=9) 141.5±58.6 (n=9) 662.9±507.5 (n=7)
G2 1464.1±636.1 (n=13) 103.9±62.8 (n=13) 692.8±340.2 (n=17)
G3 1581.5±492.8 (n=9) 70.4±56.8 (n=9) 1576.4±1424.3 (n=11)
p=0.28 (n.s.)Æ p=0.013Æ p=0.046Æ
No. of metastases
M0 1699.7±347.5 (n=15) 104.5±74.7 (n=15) 603.7±217.9 (n=19)
M>1-4 1180.5±249.4 (n=6) 105.0±62.4 (n=6) 701.1±434.4 (n=9)
M>4 1509.7±576.3 (n=7) 66.7±33.1 (n=7) 2121.4±1551.6 (n=7)
p=0.3(n.s.)Æ p=0.5 (n.s.)Æ p=0.007Æ
CA15.3
<24.9 U/mlñ 1831.0±439.4 (n=14) 90.2±64.4 (n=17) 871.4±961.3 (n=21)
>24.9 U/ml 1348.0±529.4 (n=15) 99.3±66.01 (n=15) 927.5±745.9 (n=13)
p=0.0088* p=0.5 (n.s.)* p=0.4(n.s.)*
Prostate Cancer
Parameter MMP-2 (ng/ml) MMP-9 (ng/ml) Activin A (pg/ml)
Gleason score
2-4 1616.0±314 (n=8) 51.5±22.4 (n=8) 718.9±432.4 (n=9)
5-7 1589.5±401 (n=12) 133.9±108.2 (n=12) 868.7±292.8 (n=23)
8-10 1513.7±473 (n=6) 70.4±56.8 (n=6) 1630.0±1069.5 (n=10)
p=0.72 (n.s.)Æ p=0.23 (n.s.)Æ p=0.029Æ
No. of metastases
M0 1657.9±423.3 (n=11) 87.1±103 (n=11) 700.6±314.1 (n=17)
M1-4 1514.2±527.9 (n=6) 114.7±36.2 (n=6) 1247.1.0±803.8 (n=7)
M>4 1535.3±346.7 (n=10) 112.4±39.8 (n=10) 1295.0±859.7 (n=20)
p=0.46 (n.s.)Æ p=0.77 (n.s.Æ) p=0.022Æ
PSA
<16.9 ng/mlñ 1532.9±365.3 (n=18) 70.8±77.5 (n=11) 868.5±687.6 (n=20)
>16.9 ng/ml 1686.5±536.0 (n=13) 127.4±83.1 (n=15) 1277.4±745.9 (n=23)
p=0.7 (n.s.)* p=0.021* p=0.0051*
Data are expressed as mean±SD; n= number of evaluable subjects. Due to some missing samples the number of patients in each group may vary. 
*Mann-Whitney U-test; Æ Kruskall-Wallis test; n.s.= not significant; ñcut-off value determined by ROC curve.
studies and further support the hypothesis of an active role of
these molecules in tumor progression (24-34). On the other
hand, our investigations failed to highlight any significant
difference in the plasma levels of MMP-2 or MMP-9 between
M0 and M1 patients either in breast cancer or prostate cancer.
However, in the PC group, MMP-9 levels bordered on
statistical significance. These findings fit well with the data from
some investigations (35, 36) but, at the same time, are in
contrast with those from others (28, 31-34). The discrepancies
in these results may in part, be explained by the different
criteria for selection of patients. Unlike other investigations, our
study included only patients with bone metastasis and no
clinically evident extraskeletal involvement. Additionally, the
different assay methods used and the number of subjects
included may also account for these conflicting results.
Interestingly, our data have further highlighted the significantly
higher circulating levels of activin A in the PC patients
compared to the BC patients. These findings and the strong
correlation observed between the serum concentrations of this
cytokine and the number of bone metastases and PSA levels
support the hypothesis of an active role of activin A in the
modulation of the osteoblastic activity which, in prostate cancer,
is known to be predominant and may account for the
osteoblastic reactions induced by tumor cells (8, 37-40).
Additionally, the trend towards higher levels of MMP-9 noted
in the M1 patients and the positive correlation between this
proteinase and PSA concentrations further support the concept
of a preferential involvement of MMP-9 in facilitating bone
metastasis formation in prostate cancer (3-5, 8, 9, 18, 33, 34, 36,
39). These data were suggestive of a potential clinical use of
these molecules as additional indicators of bone metastatic
spread in prostate cancer. However, ROC analysis performed
to assess this hypothesis showed that neither activin A nor
MMP-9 showed a diagnostic accuracy superior to the classical
tumor marker PSA in detecting patients with metastatic bone
disease, nor did their combination result in an improved
diagnostic efficiency. In summary, the present study suggests
that activin A and MMP-9 may have a preferential role in
facilitating bone metastasis formation in prostate cancer, while
a direct role of MMP-2 in this pathogenesis in PC and BC
remains questionable. Therefore, activin A and MMP-9 may be
regarded as possible novel therapeutic targets in the treatment
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Table IV. Sensitivity, specificity and diagnostic accuracy of activin A, MMP-2, MMP-9, CA15.3 and PSA in the detection of patients with bone
metastases.
AUC (95% CI) Cut-off value¨ Sensitivity (95%CI) Specificity (95%CI) +LR –LR PPV NPV
Breast cancer
Activin A 0.69±0.1 (0.48-0.84) 570 pg/ml 75.0 (47.6-92.6) 63.2 (38.4-83.6) 2.04 0.40 63.2 75.0
p=0.031
MMP-2 0.68±0.1 (0.47-0.83) 1195.6 ng/ml 41.7 (15.3-72.2) 100 (80.3-100) – 0.58 100 70.8
p=0.13 (n.s.)
MMP-9 0.51±0.1 (0.31-0.71) 133.2 ng/ml 93.3 (68.0-98.9) 29.4 (10.4-55.9) 1.32 0.23 53.8 83.4
p=0.68 (n.s.)
CA15.3 0.92±0.05 (0.78-0.99) 24.9 U/ml 81.2 (54.3-95.7) 88.9 (65.2-98.3) 7.31 0.21 86.6 84.2
p=0.0001
Prostate cancer
Activin A 0.77±0.07 (0.61-0.89) 740 pg/ml 85.7 (63.6-96.8) 73.7 (48.8-90.8) 3.26 0.19 78.3 82.4
p=0.0002
MMP-2 0.57±0.11 (0.39-0.78) 1482 ng/ml 62.5 (35.5-87.4) 56.2 (29.9-80.2) 1.43 0.67 58.8 60.0
p=0.48 (n.s.)
MMP-9 0.70±0.1 (0.49-0.86) 49.9 ng/ml 87.5 (61.6-98.1) 63.6 (30.9-88.8) 2.41 0.20 77.8 77.8
p=0.049
PSA 0.95±0.04 (0.82-0.99) 16.9 ng/ml 81.8 (58.1-94.4.) 100 (76.7-100) – 0.19 100 77.8
p=0.0001
¨Cut-off limits determined by ROC curve analysis; AUC: area under the ROC curve (95% confidence interval); +LR=positive likelihood ratio;
–LR=negative likelihood ratio; PPV=positive predictive value; NPV=negative predictive value; (n.s.)=not significant.
of metatastic bone disease. However, the clinical relevance of
all these molecules as additional markers of skeletal metastasis
needs to be better defined. Further studies with a larger
number of subjects are warranted by these findings.
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